Studio clinico NCT05920356 · Non-Small Cell Lung Cancer (NSCLC)

Studio clinico NCT05920356 (fase III) risulta «in reclutamento» su ClinicalTrials.gov.

Patologia: Non-Small Cell Lung Cancer (NSCLC) · Interventi registrati: Sotorasib, Pembrolizumab · Date registrate (fonte): 2023-11-16, 2027-06-30, 2023-06-27, 2026-09-11.

Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Fonte: https://clinicaltrials.gov/study/NCT05920356